氢化可的松联合氟氢可的松治疗社区获得性肺炎相关脓毒性休克:APROCCHSS 3期随机试验的亚组分析
该研究为APROCCHSS 3期随机试验的预设探索性亚组分析,纳入法国34个中心1241例脓毒性休克成人患者,其中562例为社区获得性肺炎(CAP)相关脓毒性休克。患者随机接受7天氢化可的松(50 mg静脉推注,每6小时一次)联合氟氢可的松(50 μg鼻胃管给药,每日一次)或安慰剂。CAP亚组中,激素组90天死亡109/283(39%),安慰剂组143/279(51%),OR 0.60(95%CI 0.43-0.83);非CAP亚组OR 0.95(95%CI 0.70-1.29)。CAP与非CAP亚组间90天死亡率存在显著异质性(交互作用P=0.046)。
要点
- CAP相关脓毒性休克患者中,氢化可的松联合氟氢可的松组90天死亡39%(109/283),安慰剂组51%(143/279),OR 0.60(95%CI 0.43-0.83)。
- 非CAP相关脓毒性休克患者中,激素组与安慰剂组90天死亡率无显著差异(OR 0.95,95%CI 0.70-1.29)。
- CAP与非CAP亚组间激素对90天死亡率的影响存在显著异质性(交互作用P=0.046,中等可信度)。
- CAP亚组中激素组180天内至少发生一次严重不良事件的OR为0.64(95%CI 0.46-0.89),非CAP亚组为1.02(95%CI 0.75-1.39),交互作用P=0.044。
- 该亚组分析把握度不足,无法完全区分ARDS与CAP对激素降低死亡率效应的修饰作用。
适用人群与场景
- APROCCHSS试验纳入的成人脓毒性休克患者,来自法国34个中心。
- CAP亚组:诊断为社区获得性肺炎相关脓毒性休克的患者562例(安慰剂组279例,激素组283例)。
- 非CAP亚组:非社区获得性肺炎相关脓毒性休克的患者648例(安慰剂组329例,激素组319例)。
- 31例患者无法判定CAP存在与否,未纳入亚组分析。
处置流程与药物剂量
- 氢化可的松:50 mg静脉推注,每6小时一次,每日给药,疗程7天。
- 氟氢可的松:50 μg片剂经鼻胃管给药,每日一次,疗程7天。
- 对照组接受上述药物的安慰剂,双盲设计。
研究设计与关键结果
- 研究设计:APROCCHSS为3期随机对照试验,采用2×2析因设计,2011年10月drotrecogin-alfa(活化)撤市后改为两组平行设计;本次为预设探索性亚组分析,意向性治疗分析。
- CAP亚组90天全因死亡:激素组109/283(39%),安慰剂组143/279(51%),OR 0.60(95%CI 0.43-0.83)。
- 非CAP亚组90天全因死亡:激素组148/319(46%),安慰剂组157/329(48%),OR 0.95(95%CI 0.70-1.29)。
- CAP与非CAP亚组间激素对90天死亡率影响的异质性检验:乘性交互作用P=0.046,加性交互作用P=0.046,中等可信度。
- ARDS亚组(648/1241,52%):激素组90天死亡155/320(48%),安慰剂组186/328(57%),OR 0.72(95%CI 0.53-0.98)。
- 非ARDS亚组:90天死亡OR 0.85(95%CI 0.61-1.20);ARDS与非ARDS亚组交互作用:乘性P=0.45,加性P=0.42。
- 180天内至少发生一次严重不良事件:CAP亚组OR 0.64(95%CI 0.46-0.89),非CAP亚组OR 1.02(95%CI 0.75-1.39);交互作用乘性P=0.044,加性P=0.042。
证据类型、等级与局限
- 证据类型:3期随机对照试验(APROCCHSS)的预设探索性亚组分析。
- 局限性:亚组分析把握度不足,无法完全区分ARDS与CAP对激素降低死亡率效应的修饰作用(原文自述underpowered)。
对床旁实践的改变
- 对于CAP相关脓毒性休克成人患者,氢化可的松联合氟氢可的松(7天方案)可降低90天死亡率(OR 0.60,95%CI 0.43-0.83)。
- 对于非CAP相关脓毒性休克患者,该激素方案未显示显著降低90天死亡率(OR 0.95,95%CI 0.70-1.29)。
- CAP亚组中激素组严重不良事件风险降低(OR 0.64,95%CI 0.46-0.89),非CAP亚组未见此效应(OR 1.02,95%CI 0.75-1.39)。
- 作者认为,该亚组分析把握度不足,无法完全区分ARDS与CAP对激素疗效的修饰作用。
指南或共识出处
- APROCCHSS试验(NCT00625209)的预设亚组分析,发表于Lancet Respiratory Medicine。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Glucocorticoids probably improve outcomes in patients hospitalised for community acquired pneumonia (CAP). In this a priori planned exploratory subgroup analysis of the phase 3 randomised controlled Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHSS) trial, we aimed to investigate responses to hydrocortisone plus fludrocortisone between CAP and non-CAP related septic shock.
METHODS: APROCCHSS was a randomised controlled trial that investigated the effects of hydrocortisone plus fludrocortisone, drotrecogin-alfa (activated), or both on mortality in septic shock in a two-by-two factorial design; after drotrecogin-alfa was withdrawn on October 2011, from the market, the trial continued on two parallel groups. It was conducted in 34 centres in France. In this subgroup study, patients with CAP were a preselected subgroup for an exploratory secondary analysis of the APROCCHSS trial of hydrocortisone plus fludrocortisone in septic shock. Adults with septic shock were randomised 1:1 to receive, in a double-blind manner, a 7-day treatment with daily administration of intravenous hydrocortisone 50 mg bolus every 6h and a tablet of 50 μg of fludrocortisone via the nasogastric tube, or their placebos. The primary outcome was 90-day all-cause mortality. Secondary outcomes included all-cause mortality at intensive care unit (ICU) and hospital discharge, 28-day and 180-day mortality, the number of days alive and free of vasopressors, mechanical ventilation, or organ failure, and ICU and hospital free-days to 90-days. Analysis was done in the intention-to-treat population. The trial was registered at ClinicalTrials.gov (NCT00625209).
FINDINGS: Of 1241 patients included in the APROCCHSS trial, CAP could not be ruled in or out in 31 patients, 562 had a diagnosis of CAP (279 in the placebo group and 283 in the corticosteroid group), and 648 patients did not have CAP (329 in the placebo group and 319 in the corticosteroid group). In patients with CAP, there were 109 (39%) deaths of 283 patients at day 90 with hydrocortisone plus fludrocortisone and 143 (51%) of 279 patients receiving placebo (odds ratio [OR] 0·60, 95% CI 0·43-0·83). In patients without CAP, there were 148 (46%) deaths of 319 patients at day 90 in the hydrocortisone and fludrocortisone group and 157 (48%) of 329 patients in the placebo group (OR 0·95, 95% CI 0·70-1·29). There was significant heterogeneity in corticosteroid effects on 90-day mortality across subgroups with CAP and without CAP (p=0·046 for both multiplicative and additive interaction tests; moderate credibility). Of 1241 patients included in the APROCCHSS trial, 648 (52%) had ARDS (328 in the placebo group and 320 in the corticosteroid group). There were 155 (48%) deaths of 320 patients at day 90 in the corticosteroid group and 186 (57%) of 328 patients in the placebo group. The OR for death at day 90 was 0·72 (95% CI 0·53-0·98) in patients with ARDS and 0·85 (0·61-1·20) in patients without ARDS (p=0·45 for multiplicative interaction and p=0·42 for additive interaction). The OR for observing at least one serious adverse event (corticosteroid group vs placebo) within 180 days post randomisation was 0·64 (95% CI 0·46-0·89) in the CAP subgroup and 1·02 (0·75-1·39) in the non-CAP subgroup (p=0·044 for multiplicative interaction and p=0·042 for additive interaction).
INTERPRETATION: In a pre-specified subgroup analysis of the APROCCHSS trial of patients with CAP and septic shock, hydrocortisone plus fludrocortisone reduced mortality as compared with placebo. Although a large proportion of patients with CAP also met criteria for ARDS, the subgroup analysis was underpowered to fully discriminate between ARDS and CAP modifying effects on mortality reduction with corticosteroids. There was no evidence of a significant treatment effect of corticosteroids in the non-CAP subgroup.
FUNDING: Programme Hospitalier de Recherche Clinique of the French Ministry of Health, by Programme d'Investissements d'Avenir, France 2030, and IAHU-ANR-0004.
参考来源
- Heming N, Renault A, Kuperminc E, et al. Hydrocortisone plus fludrocortisone for community acquired pneumonia-related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trial. Lancet Respir Med. 2024. PMID: 38310918. doi:10.1016/S2213-2600(23)00430-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。